Eddie Hickman
Stock Analyst at Guggenheim
(4.51)
# 1,054
Out of 4,609 analysts
48
Total ratings
64.3%
Success rate
30.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMN ProMIS Neurosciences | Maintained: Buy | $35 → $69 | $13.33 | +417.63% | 5 | Jul 28, 2026 | |
| ZVRA Zevra Therapeutics | Maintained: Buy | $29 → $24 | $11.88 | +102.02% | 8 | Jul 24, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintained: Buy | $90 → $89 | $65.33 | +36.23% | 16 | Jul 21, 2026 | |
| ATAI AtaiBeckley | Downgraded: Hold | n/a | $7.18 | - | 3 | Jul 16, 2026 | |
| GHRS GH Research | Maintained: Buy | $29 → $34 | $30.64 | +10.97% | 4 | Mar 9, 2026 | |
| HELP Cybin | Maintained: Buy | $39 → $48 | $11.10 | +332.43% | 3 | Dec 3, 2025 | |
| OTLK Outlook Therapeutics | Downgraded: Hold | n/a | $0.9725 | - | 7 | Aug 28, 2025 | |
| IMVT Immunovant | Reiterated: Buy | $44 | $39.74 | +10.72% | 2 | Aug 11, 2025 |
ProMIS Neurosciences
Jul 28, 2026
Maintained: Buy
Price Target: $35 → $69
Current: $13.33
Upside: +417.63%
Zevra Therapeutics
Jul 24, 2026
Maintained: Buy
Price Target: $29 → $24
Current: $11.88
Upside: +102.02%
Tarsus Pharmaceuticals
Jul 21, 2026
Maintained: Buy
Price Target: $90 → $89
Current: $65.33
Upside: +36.23%
AtaiBeckley
Jul 16, 2026
Downgraded: Hold
Price Target: n/a
Current: $7.18
Upside: -
GH Research
Mar 9, 2026
Maintained: Buy
Price Target: $29 → $34
Current: $30.64
Upside: +10.97%
Cybin
Dec 3, 2025
Maintained: Buy
Price Target: $39 → $48
Current: $11.10
Upside: +332.43%
Outlook Therapeutics
Aug 28, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.9725
Upside: -
Immunovant
Aug 11, 2025
Reiterated: Buy
Price Target: $44
Current: $39.74
Upside: +10.72%